Abstract
Thrombosis of a coronary artery is the most common cause of myocardial infarction (DeWood et al. 1980). Thrombolytic therapy, when instituted timely, has been shown capable of reducing morbidity and mortality (GISSI 1986). Problems remain, however, including resistance to fibrinolytic therapy, delays in reperfusion, reocclusion after successful thrombolysis and serious hemorrhage (Coller 1990).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bode C, Matsueda GR, Hui KY, Haber E (1985) Antibody directed urokinase: A specific fibrinolytic agent. Science 229: 765–767
Bode C, Runge MS, Newell JB, Matsueda GR, Haber E (1987a) Characterisation of a urokinase-antibody conjugate: a plasminogen activator targeted to fibrin. J Biol Chem 262: 10819–10823
Bode C, Runge MS, Matsueda GR, Haber E (1987b) Thrombolysis by a fibrin-specific antibody fab’-urokinase conjugate. J Mol Cell Cardiol 19: 159–166
Bode C, Schonermark S, Runge MS, Eberle T, Matsueda GR, Schuler G, Kübler W, Haber E (1988) Steigerung der thrombolytischen Wirksamkeit von Tissue Plasminogen Aktivator (TPA) durch ein Antikörper-(Fab’)2 Doppelmolekül. Z Kardiol 77: 19 (abstract)
Bode C, Meinhardt G, Runge MS, Eberle T, Schuler G, Kübler W, Haber E (1989a) Conjugation of urokinase to an antiplatelet antibody results in a more potent fibrinolytic agent. Thromb Haemostas 62: 483 (abstract)
Bode C, Runge MS, Branscomb EE, Newell JB, Matsueda GR, Haber E (1989b) Antibody-directed fibrinolysis: an antibody specific for both fibrin and tissue plasminogen activator. 264: 944–948
Bode C, Runge MS, Schonermark S, Eberle T, Newell JB, Kübler W, Haber E (1990) Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody. Circulation (in press)
Carson DA, Freimark BD (1986) Human lymphocyte hybridomas and monoclonal antibodies. Adv Immunol 38: 275–311
Coller BS (1985) A new murine monoclonal antibody reports an activation-dependant change in the conformation and/or microenvironment of the platelet glycoprotein Iib/IIIa complex. J Clin Invest 76: 101–108
Coller BS (1990) Platelets and thrombolytic therapy. N Engl J Med 322: 33–42
De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303: 897–902
Hui KY, Haber E, Matsueda GR (1983) Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Sience 222: 1129–1131
Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H (1988) Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia Coli. Proc Natl Acad Sci USA 85: 5879–5883
Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D (1989) Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 79: 920–928
Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497
Love TW, Runge MS, Savard CE, Schnee JM, Matsueda GR, Quertermous T, Haber E (1989) Antifibrin antibody-tPA recombinant molecules: structure function relationships. Thromb Haemostas 62: 483 (abstract)
Runge MS, Bode C, Matsueda GR, Haber E (1987) Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 84: 7659–7662
Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T (1987) Construction and Expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci USA 84: 6904–6908
Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, Candela RJ, Abbottsmith CW, Pinkerton CA, Stump DC, Collen D, Lee KL, Pitt B, Kline EM, Boswick JM, O’Neill WW, Stack RS and the TAMI Study Group (1988) Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 77: 1100–1107
Verhoeyen M, Milstein C, Winter G (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239:1534–1536.
Wetzel R (1988) Active immunoglobulin fragments synthesized in E. Coli—from Fab to Scantibodies. Protein Engineering 2: 169–170
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bode, C., Runge, M.S., Nordt, T., Eberle, T., Kübler, W., Haber, E. (1990). Antibody-Mediated Thrombolysis: Promise and Problems. In: Harenberg, J., Heene, D.L., Stehle, G., Schettler, G. (eds) New Trends in Haemostasis. Veröffentlichungen aus der Geomedizinischen Forschungsstelle der Heidelberger Akademie der Wissenschaften, vol 1990 / 1990/3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84318-1_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-84318-1_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53275-0
Online ISBN: 978-3-642-84318-1
eBook Packages: Springer Book Archive